RxSight, based in Aliso Viejo, California, specializes in ophthalmic goods and continues to be an active player in the medical technology sector. The company maintains a solid balance sheet with more cash than debt, positioning it well for future growth opportunities. The company maintains a solid balance sheet with more cash than debt, positioning it well for future growth opportunities.
RxSight, based in Aliso Viejo, California, specializes in ophthalmic goods and continues to be an active player in the medical technology sector. The company maintains a solid balance sheet with more cash than debt, positioning it well for future growth opportunities.
RxSight, based in Aliso Viejo, California, specializes in ophthalmic goods and continues to be an active player in the medical technology sector.
In other recent news, RxSight Inc. has been the subject of several recent analyst adjustments. Stifel has downgraded their rating on the company’s shares and reduced their price target due to concerns about competition and international expansion efforts. The firm’s decision followed a review of RxSight’s Q4 2024 preliminary results, which reported a total revenue of $40.2 million, aligning with both Stifel’s and consensus estimates.
In contrast, Needham & Company maintained a positive stance on RxSight, reiterating a Buy rating. The company’s revenue forecast for 2025 surpassed consensus estimates, projecting revenues to be between $185 million and $197 million. However, Stifel and Wells Fargo (NYSE:WFC) downgraded RxSight’s stock due to slowing adoption projections and limited growth potential respectively.
UBS initiated coverage on RxSight with a Buy rating, highlighting the company’s strong position in the U.S. cataract surgery market and projecting over 20% sales growth through 2028. These recent developments reflect a diverse range of perspectives from analysts regarding the future of RxSight.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.